Literature DB >> 29326427

Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats.

Denise Van der Graaff1,2, Wilhelmus J Kwanten1,2, Filip J Couturier2, Jesse S Govaerts2, Wim Verlinden1,2, Isabel Brosius2, Michiel D'Hondt2, Ann Driessen3, Benedicte Y De Winter2, Joris G De Man2, Peter P Michielsen1,2, Sven M Francque4,5.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease. The presence of portal hypertension has been demonstrated in NAFLD prior to development of inflammation or fibrosis, and is a result of extrahepatic and intrahepatic factors, principally driven by vascular dysfunction. An increased intrahepatic vascular resistance potentially contributes to progression of NAFLD via intralobular hypoxia. However, the exact mechanisms underlying vascular dysfunction in NAFLD remain unknown. This study investigates systemic hemodynamics and both aortic and intrahepatic vascular reactivity in a rat model of severe steatosis. Wistar rats were fed a methionine-choline-deficient diet, inducing steatosis, or control diet for 4 weeks. In vivo hemodynamic measurements, aortic contractility studies, and in situ liver perfusion experiments were performed. The mean arterial blood pressure was lower and portal blood pressure was higher in steatosis compared to controls. The maximal contraction force in aortic rings from steatotic rats was markedly reduced compared to controls. While blockade of nitric oxide (NO) production did not reveal any differences, cyclooxygenase (COX) blockade reduced aortic reactivity in both controls and steatosis, whereas effects were more pronounced in controls. Effects could be attributed to COX-2 iso-enzyme activity. In in situ liver perfusion experiments, exogenous NO donation or endogenous NO stimulation reduced the transhepatic pressure gradient (THPG), whereas NO synthase blockade increased the THPG only in steatosis, but not in controls. Alpha-1-adrenergic stimulation and endothelin-1 induced a significantly more pronounced increase in THPG in steatosis compared to controls. Our results demonstrate that severe steatosis, without inflammation or fibrosis, induces portal hypertension and signs of a hyperdynamic circulation, accompanied by extrahepatic arterial hyporeactivity and intrahepatic vascular hyperreactivity. The arterial hyporeactivity seems to be NO-independent, but appears to be mediated by specific COX-2-related mechanisms. Besides, the increased intrahepatic vascular resistance in steatosis appears not to be NO-related but rather to vasoconstrictor hyperreactivity.

Entities:  

Mesh:

Year:  2018        PMID: 29326427     DOI: 10.1038/s41374-017-0018-z

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

Review 1.  Role of liver sinusoidal endothelial cells in liver diseases.

Authors:  Jordi Gracia-Sancho; Esther Caparrós; Anabel Fernández-Iglesias; Rubén Francés
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-15       Impact factor: 46.802

Review 2.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945

Review 3.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

4.  Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices.

Authors:  Anouk Oldenburger; Gerald Birk; Marco Schlepütz; Andre Broermann; Birgit Stierstorfer; Steven S Pullen; Jörg F Rippmann
Journal:  Pharmacol Res Perspect       Date:  2021-05

5.  Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis.

Authors:  Geraldine F Clough; Andrew J Chipperfield; Marjola Thanaj; Eleonora Scorletti; Philip C Calder; Christopher D Byrne
Journal:  Front Physiol       Date:  2020-06-03       Impact factor: 4.566

6.  The impact of hepatic steatosis on portal hypertension.

Authors:  Georg Semmler; Bernhard Scheiner; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; David Chromy; Albert Friedrich Stättermayer; Michael Trauner; Mattias Mandorfer; Arnulf Ferlitsch; Thomas Reiberger
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

7.  Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD.

Authors:  Denise van der Graaff; Shivani Chotkoe; Benedicte De Winter; Joris De Man; Christophe Casteleyn; Jean-Pierre Timmermans; Isabel Pintelon; Luisa Vonghia; Wilhelmus J Kwanten; Sven Francque
Journal:  JHEP Rep       Date:  2021-11-25

Review 8.  Platelets in Non-alcoholic Fatty Liver Disease.

Authors:  Andrea Dalbeni; Marco Castelli; Mirko Zoncapè; Pietro Minuz; David Sacerdoti
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

9.  Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging.

Authors:  Csaba Adori; Teresa Daraio; Raoul Kuiper; Swapnali Barde; Lubica Horvathova; Takashi Yoshitake; Robert Ihnatko; Ismael Valladolid-Acebes; Pauline Vercruysse; Ashley M Wellendorf; Roberto Gramignoli; Bela Bozoky; Jan Kehr; Elvar Theodorsson; Jose A Cancelas; Boris Mravec; Carl Jorns; Ewa Ellis; Jan Mulder; Mathias Uhlén; Christina Bark; Tomas Hökfelt
Journal:  Sci Adv       Date:  2021-07-21       Impact factor: 14.136

10.  Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats.

Authors:  Carla Cremonese; Robert Schierwagen; Frank Erhard Uschner; Sandra Torres; Olaf Tyc; Cristina Ortiz; Martin Schulz; Alexander Queck; Glen Kristiansen; Michael Bader; Tilman Sauerbruch; Ralf Weiskirchen; Thomas Walther; Jonel Trebicka; Sabine Klein
Journal:  Int J Mol Sci       Date:  2020-05-07       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.